Literature DB >> 18305066

Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue.

M Schumann1, J F Richter, I Wedell, V Moos, M Zimmermann-Kordmann, T Schneider, S Daum, M Zeitz, M Fromm, J D Schulzke.   

Abstract

BACKGROUND AND AIMS: The alpha(2)-gliadin-33mer has been shown to be important in the pathogenesis of coeliac disease. We aimed to study mechanisms of its epithelial translocation and processing in respect to transcytotic and paracellular pathways.
METHODS: Transepithelial passage of a fluorescence-labelled alpha(2)-gliadin-33mer was studied in Caco-2 cells by using reverse-phase high-performance liquid chromatography, mass spectrometry, confocal laser scanning microscopy (LSM) and fluorescence activated cell sorting (FACS). Endocytosis mechanisms were characterised with rab-GFP constructs transiently transfected into Caco-2 cells and in human duodenal biopsy specimens.
RESULTS: The alpha(2)-gliadin-33mer dose-dependently crossed the epithelial barrier in the apical-to-basal direction. Degradation analysis revealed translocation of the 33mer polypeptide in the uncleaved as well as in the degraded form. Transcellular passage was identified by confocal LSM, inhibitor experiments and FACS. Rab5 but not rab4 or rab7 vesicles were shown to be part of the transcytotic pathway. After pre-incubation with interferon-gamma, translocation of the 33mer was increased by 40%. In mucosal biopsies of the duodenum, epithelial 33mer uptake was significantly higher in untreated coeliac disease patients than in healthy controls or coeliac disease patients on a gluten-free diet.
CONCLUSION: Epithelial translocation of the alpha(2)-gliadin-33mer occurs by transcytosis after partial degradation through a rab5 endocytosis compartment and is regulated by interferon-gamma. Uptake of the 33mer is higher in untreated coeliac disease than in controls and coeliac disease patients on a gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305066     DOI: 10.1136/gut.2007.136366

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  44 in total

Review 1.  Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes.

Authors:  C Osorio; N Wen; R Gemini; R Zemetra; D von Wettstein; S Rustgi
Journal:  Funct Integr Genomics       Date:  2012-06-26       Impact factor: 3.410

Review 2.  Proteomic analyses lead to a better understanding of celiac disease: focus on epitope recognition and autoantibodies.

Authors:  Valli De Re; Maria Paola Simula; Vincenzo Canzonieri; Renato Cannizzaro
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

3.  [New therapeutic approaches to special diseases of the small intestine].

Authors:  M Schumann; K Herrlinger; M Zeitz; E F Stange
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

Review 4.  Celiac disease: from etiological factors to evolving diagnostic approaches.

Authors:  Anantdeep Kaur; Olga Shimoni; Michael Wallach
Journal:  J Gastroenterol       Date:  2017-06-19       Impact factor: 7.527

5.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

6.  New and developing therapies for celiac disease.

Authors:  Christina A Tennyson; Suzanne K Lewis; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

7.  Immunopathogenesis of celiac disease.

Authors:  Jason Tye-Din; Robert Anderson
Journal:  Curr Gastroenterol Rep       Date:  2008-10

8.  Recent advances in celiac disease.

Authors:  Hugh James Freeman; Angeli Chopra; Michael Tom Clandinin; Alan Br Thomson
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

9.  Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides.

Authors:  Michael T Bethune; Matthew Siegel; Samuel Howles-Banerji; Chaitan Khosla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

10.  Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques.

Authors:  Kaushiki Mazumdar; Xavier Alvarez; Juan T Borda; Jason Dufour; Edith Martin; Michael T Bethune; Chaitan Khosla; Karol Sestak
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.